BRPI0906519A2 - Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese - Google Patents

Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese

Info

Publication number
BRPI0906519A2
BRPI0906519A2 BRPI0906519-9A BRPI0906519A BRPI0906519A2 BR PI0906519 A2 BRPI0906519 A2 BR PI0906519A2 BR PI0906519 A BRPI0906519 A BR PI0906519A BR PI0906519 A2 BRPI0906519 A2 BR PI0906519A2
Authority
BR
Brazil
Prior art keywords
kinase
triazolo
synthesis
pyrimidine compounds
kinase inhibitors
Prior art date
Application number
BRPI0906519-9A
Other languages
English (en)
Inventor
Christoph Martin Dehnhardt
Aranapakam Mudumbai Venkatesan
Efren Guillermo Delos Santos
Zecheng Chen
Osvaldo Dos Santos
Natasja Brooijmans
Arie Zask
Jeroen Cunera Verheijen
Semiranis Ayral-Kaloustian
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of BRPI0906519A2 publication Critical patent/BRPI0906519A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0906519-9A 2008-01-15 2009-01-14 Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese BRPI0906519A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2108408P 2008-01-15 2008-01-15
US3468008P 2008-03-07 2008-03-07
PCT/US2009/030939 WO2009091788A1 (en) 2008-01-15 2009-01-14 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses

Publications (1)

Publication Number Publication Date
BRPI0906519A2 true BRPI0906519A2 (pt) 2015-07-14

Family

ID=40377318

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906519-9A BRPI0906519A2 (pt) 2008-01-15 2009-01-14 Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese

Country Status (21)

Country Link
US (1) US20090181963A1 (pt)
EP (1) EP2252296A1 (pt)
JP (1) JP2011510010A (pt)
KR (1) KR20100113567A (pt)
CN (1) CN102014914A (pt)
AP (1) AP2010005346A0 (pt)
AU (1) AU2009205501A1 (pt)
BR (1) BRPI0906519A2 (pt)
CA (1) CA2712267A1 (pt)
CO (1) CO6321259A2 (pt)
CR (1) CR11568A (pt)
DO (1) DOP2010000217A (pt)
EA (1) EA201001017A1 (pt)
EC (1) ECSP10010346A (pt)
IL (1) IL206820A0 (pt)
MA (1) MA32341B1 (pt)
MX (1) MX2010007746A (pt)
NI (1) NI201000119A (pt)
SV (1) SV2010003621A (pt)
WO (1) WO2009091788A1 (pt)
ZA (2) ZA201004603B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
EP2276750A2 (en) * 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2445346A4 (en) * 2009-06-24 2012-12-05 Genentech Inc OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
TW201105662A (en) * 2009-07-07 2011-02-16 Pathway Therapeutics Ltd Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EP2531194B1 (en) 2010-02-03 2018-04-18 Signal Pharmaceuticals, LLC Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
WO2012047538A1 (en) 2010-10-06 2012-04-12 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2013067141A1 (en) * 2011-11-01 2013-05-10 Exelixis, Inc. N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies
WO2013152717A1 (zh) * 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
CA2868392A1 (en) 2012-05-23 2013-11-28 Estelle DOUDEMENT Compositions and methods of obtaining and using endoderm and hepatocyte cells
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
NZ730189A (en) 2013-04-17 2018-09-28 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
JP6382948B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
KR102271344B1 (ko) 2013-04-17 2021-07-01 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
AU2014254053B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with Dihydropyrazino-Pyrazines
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
BR112015026021A2 (pt) 2013-04-17 2017-07-25 Signal Pharm Llc terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
KR102221005B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 전립선암 치료를 위한 디하이드로피라지노-피라진 화합물 및 안드로겐 수용체 길항제를 포함하는 조합 요법
WO2014193912A1 (en) 2013-05-29 2014-12-04 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP6441910B2 (ja) 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3143021B1 (en) * 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridines and pyrazolopyrimidines
WO2017087818A1 (en) * 2015-11-19 2017-05-26 The Regents Of The University Of Michigan Dual src/p38 kinase inhibitor compounds and their use as therapeutic agents
MX2019013862A (es) 2017-05-23 2020-01-20 Mei Pharma Inc Terapia de combinacion.
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2020063636A1 (zh) * 2018-09-27 2020-04-02 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
CN113549080B (zh) * 2021-08-27 2023-05-16 中国医学科学院放射医学研究所 一类1,2,3-三氮唑并嘧啶类化合物、其制备方法和用途
KR20240015978A (ko) 2022-07-28 2024-02-06 박수산 다층 수력 발전시스템

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives

Also Published As

Publication number Publication date
JP2011510010A (ja) 2011-03-31
MA32341B1 (fr) 2011-06-01
KR20100113567A (ko) 2010-10-21
AP2010005346A0 (en) 2010-08-31
CR11568A (es) 2010-08-11
AU2009205501A1 (en) 2009-07-23
CN102014914A (zh) 2011-04-13
EP2252296A1 (en) 2010-11-24
ZA201005793B (en) 2011-04-28
SV2010003621A (es) 2011-07-05
CO6321259A2 (es) 2011-09-20
MX2010007746A (es) 2010-08-18
CA2712267A1 (en) 2009-07-23
ZA201004603B (en) 2011-03-30
NI201000119A (es) 2011-05-04
DOP2010000217A (es) 2010-07-31
ECSP10010346A (es) 2010-08-31
IL206820A0 (en) 2010-12-30
US20090181963A1 (en) 2009-07-16
WO2009091788A1 (en) 2009-07-23
EA201001017A1 (ru) 2011-02-28

Similar Documents

Publication Publication Date Title
BRPI0906519A2 (pt) Compostos de 3h--[1,2,3]triazolo[4,5-d]pirimidina, seu uso como mtor cinase e inibidores de pi3 cinase, e sua síntese
BRPI0817681A2 (pt) Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
LTPA2020504I1 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip Trk kinazės slopikliai
BRPI0813831A2 (pt) Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
AU2008228964A8 (en) Pyrazolopyrimidine Analogs and their use as mTOR kinase and PI3 kinase inhibitors
BRPI0716749A2 (pt) Compostos pirido (2,3-d) pirimidinona e seu uso como inibidores pi3
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
ES2970354T3 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de Janus quinasas
DK2384326T3 (da) Pyrrolo[2,3-d]pyrimidinforbindelser
HK1143154A1 (en) Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors b[23-d]
DK1973910T3 (da) Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
IL223253B (en) History of 2-(piperidin-2-yl)-pyrazolo[1,5-a]pyrimidine and their use in the preparation of drugs against pneumovirina
DK2049500T3 (da) Cyclopenta [d]-pyrimidiner som AKT-proteinkinase-inhibitorer
HK1158947A1 (en) Macrocyclic pyrimidines as protein kinase inhibitors
HK1151286A1 (en) 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as pi-3 kinases inhibitors pi3
NO20084526L (no) Tienpyrimidiner med MNKL/MNK2 inhiberende aktivitet for farmasøytiske sammensetninger
PL2217578T3 (pl) Związki [1,2,4]triazolo[1,5-a]pirydyny i [1,2,4]triazolo[1,5-c]pirymidyny i ich zastosowanie
BR112013017672A2 (pt) composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor
BRPI0919810A2 (pt) compostos heterocíclicos contendo nitrogênio, sua preparação e seu uso como medicamentos antibacterianos
BRPI0815043A2 (pt) mcp-1 mutantes antagonistas de glicosaminoglicanos e métodos para o seu uso
HK1142906A1 (en) Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
BRPI0924183A2 (pt) inibidores de proteína quinase, formas cristalinas, formulações farmacêuticas e uso
EP2525659A4 (en) PYRAZOLO [1,5-A] PYRIMIDINES COMPOUNDS AS MTOR INHIBITORS
BRPI1008850A2 (pt) [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.